Compare Gogoro Inc (GGR) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gogoro Inc vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Gogoro Inc trades at $3.02 (market cap $56.21M), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.72 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 1045× Gogoro Inc's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Gogoro Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gogoro Inc for 14 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days on average.
| GGR | TAK | |
|---|---|---|
Market Cap | $56.21M | $58.74B |
Volume | 14,026 | 3,110,994 |
Sector | Consumer Cyclical | Health |
52-Week High | $5.15 | $19.05 |
52-Week Low | $2.20 | $13.23 |
Typical Hold Time | 14 Days | 1 Days |
Enterprise Value | $342.65M | $86.65B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GGR trades at $2.99, down 6.27% today, with a bullish technical signal from moving averages but negative profitability metrics including a -16.68% net income margin. Recent developments include new board appointments and a $61.8 million equity investment announced in October 2026. The company shows revenue growth from $281 million in 2025 to $286 million projected for 2026, though net losses persist.
The outlook remains cautious with 100% hold ratings from analysts. Investment appeal lies in the low P/S of 0.18 and EV/EBITDA of 6.38, but risks include sustained negative cash flow and high debt-to-asset ratio of 60%. Positive technical momentum contrasts with fundamental challenges in achieving profitability.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gogoro Inc
Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
